You know, the FDA did approve uh brensicatib for all patients with bronchiectasis, but of course, it is a question as to um which patient really potentially would benefit the most. And I think the first thing on this question is that the drug uh appears to be very safe and well tolerated. So it does make it attractive to, to prescribe fairly widely in our patients with bronchiectasis. But I do think we all have to remember that bronchiectasis is a very heterogeneous disease and many patients will be diagnosed with bronchiectasis even when they're asymptomatic. They have a CT scan for another reason, and they may have some bronchiectasis on the CT. Or they may be the kind of patient that has, you know, intermittent cough, maybe one exacerbation every 2 or 3 years, or they may be the kind of patient that really was enrolled in the trials and that's the patient with frequent exacerbations despite being on good standard therapy. So I think it's fairly clear that patients who fit the criteria that we use in the trial, that's the 2 or more exacerbations per year, clearly are good candidates for uh using uh uh for forensicatib, um, you know, patients who have less frequent exacerbations but are have more um frequent symptoms, daily symptoms, you know, bothersome cough, sputum production. Obviously they're a good target likely for this um uh compound, but again, that was not the type of patient. To really, um, you know, have mycobacterial infections, those patients tend not to exacerbate all that frequently in the classic sense. Do patients with, uh, Mac infection, for example, and bronchiectasis benefit from this compound? We don't know because those patients were excluded from the trial. So I do think we have some clear-cut candidates for this, um, type of drug. Uh, but it becomes a little, uh, more murky, uh, in a patient who's less symptomatic or asymptomatic. Now, a, a question does arise, is this, is this, uh, compound particularly uh Is this, uh, brensicib possibly disease modifying, like would there be a reason to use this at the first time of diagnosis, um, in order to prevent progression? And of course, that's a question that has not been explored yet in any meaningful way to give an answer to that.
Presenter
